|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
JP5879256B2
(ja)
|
2009-05-02 |
2016-03-08 |
ジェンザイム・コーポレーション |
神経変性障害のための遺伝子治療
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
EP2561075B1
(en)
|
2010-04-23 |
2018-06-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
EP2826860B1
(en)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
EP3318635A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
HRP20171334T1
(hr)
|
2011-04-22 |
2017-11-17 |
The Regents Of The University Of California |
Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
|
|
CN105377039A
(zh)
*
|
2013-05-15 |
2016-03-02 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
US11136557B2
(en)
|
2013-05-31 |
2021-10-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
KR102537394B1
(ko)
|
2014-03-17 |
2023-05-30 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
|
EP4410805A3
(en)
|
2014-03-18 |
2024-11-27 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
IL248102B
(en)
|
2014-05-02 |
2022-07-01 |
Genzyme Corp |
aav vectors for gene therapy of the central nervous system and retina
|
|
AR100419A1
(es)
*
|
2014-05-14 |
2016-10-05 |
Esteve Labor Dr |
Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
AU2015335923B2
(en)
|
2014-10-21 |
2021-04-29 |
University Of Massachusetts |
Recombinant AAV variants and uses thereof
|
|
TN2017000354A1
(en)
|
2015-02-10 |
2019-01-16 |
Genzyme Corp |
VARIANT RNAi
|
|
TN2017000353A1
(en)
*
|
2015-02-10 |
2019-01-16 |
Genzyme Corp |
Enhanced delivery of viral particles to the striatum and cortex
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
MY187898A
(en)
|
2015-03-02 |
2021-10-27 |
Adverum Biotechnologies Inc |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
AU2016228751B2
(en)
*
|
2015-03-11 |
2022-01-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rp2 vectors for treating x-linked retinitis pigmentosa
|
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
アデノ随伴ウイルス変異体及びその使用方法
|
|
RS61907B1
(sr)
|
2015-04-06 |
2021-06-30 |
Subdomain Llc |
Polipeptidi koji sadrže de novo vezujući domen i njihova primena
|
|
EP3280451B8
(en)
|
2015-04-08 |
2019-09-25 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
BR112018003665A2
(en)
|
2015-09-28 |
2018-09-25 |
The University Of North Carolina At Chapel Hill |
methods and compositions for antibody evasion viral vectors
|
|
CA3002980A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
KR102423442B1
(ko)
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
|
IL259964B
(en)
*
|
2015-12-15 |
2022-09-01 |
Genzyme Corp |
Adenovirus-associated vectors for the treatment of mucolipodosis type ii
|
|
WO2017136536A1
(en)
*
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
US11060088B2
(en)
|
2016-02-12 |
2021-07-13 |
University Of Massachusetts |
Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
|
|
WO2017147477A1
(en)
*
|
2016-02-26 |
2017-08-31 |
University Of Florida Research Foundation, Inc. |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
CA3024449A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
US11197936B2
(en)
*
|
2016-07-08 |
2021-12-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving RDH12
|
|
US11458211B2
(en)
|
2016-07-12 |
2022-10-04 |
The University Of Manchester |
Gene therapy
|
|
EP3827812B1
(en)
|
2016-07-29 |
2025-10-29 |
The Regents of the University of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
US20190262373A1
(en)
*
|
2016-08-16 |
2019-08-29 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
WO2018035503A1
(en)
*
|
2016-08-18 |
2018-02-22 |
The Regents Of The University Of California |
Crispr-cas genome engineering via a modular aav delivery system
|
|
WO2018035457A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Calimmune, Inc. |
Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
|
|
CN109843306A
(zh)
*
|
2016-08-19 |
2019-06-04 |
卡琳缪恩股份有限公司 |
使用自身互补型重组腺相关病毒治疗病症的方法和组合物
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
TW201819398A
(zh)
|
2016-09-28 |
2018-06-01 |
美商寇峇有限公司 |
治療性肽
|
|
EP3518985A4
(en)
*
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
EP3526333A4
(en)
|
2016-10-13 |
2020-07-29 |
University of Massachusetts |
AAV CAPSIDE DESIGNS
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
KR20250121159A
(ko)
|
2016-12-07 |
2025-08-11 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
인터류킨-1 수용체 길항제(IL-1RA) cDNA
|
|
WO2018145009A1
(en)
*
|
2017-02-06 |
2018-08-09 |
University Of Tennessee Research Foundation |
Dna-zyme based methods & compositions for treating huntington's disease
|
|
WO2018156892A1
(en)
|
2017-02-23 |
2018-08-30 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
WO2018191450A2
(en)
|
2017-04-14 |
2018-10-18 |
National Taiwan University Hospital |
Gene therapy for aadc deficiency
|
|
WO2018200419A1
(en)
*
|
2017-04-23 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Viral vectors comprising engineered aav capsids and compositions containing the same
|
|
JP2020518259A
(ja)
*
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
WO2018208972A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
|
JP7330899B2
(ja)
|
2017-05-10 |
2023-08-22 |
マサチューセッツ アイ アンド イヤー インファーマリー |
ウイルスのアセンブリ活性化タンパク質（ａａｐ）依存性を改変する方法および組成物
|
|
CN110997693A
(zh)
|
2017-06-07 |
2020-04-10 |
阿德克斯公司 |
τ聚集抑制剂
|
|
WO2019006182A1
(en)
*
|
2017-06-30 |
2019-01-03 |
The Regents Of The University Of California |
VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF
|
|
KR20200036912A
(ko)
|
2017-07-31 |
2020-04-07 |
리플렉션 바이오테크놀러지스 리미티드 |
안과 질환을 위한 세포 모델 및 치료요법
|
|
JP7221275B2
(ja)
*
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖを送達するための組成物および方法
|
|
JP2020534788A
(ja)
|
2017-08-28 |
2020-12-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノ随伴ウイルスカプシド変異体及びその使用方法
|
|
KR102686857B1
(ko)
|
2017-09-22 |
2024-07-18 |
젠자임 코포레이션 |
변이체 RNAi
|
|
WO2019060649A1
(en)
*
|
2017-09-22 |
2019-03-28 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
|
|
CA3075643A1
(en)
|
2017-09-22 |
2019-03-28 |
University Of Massachusetts |
Sod1 dual expression vectors and uses thereof
|
|
NZ763617A
(en)
*
|
2017-10-16 |
2026-01-30 |
Vigeneron Gmbh |
Aav vectors
|
|
JP7420710B2
(ja)
*
|
2017-10-20 |
2024-01-23 |
アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） |
組換えａａｖ９由来ベクターの治療有効量の網膜下送達を含む、対象の錐体視細胞において目的のポリヌクレオチドを発現させる方法
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
IL274677B2
(en)
|
2017-11-14 |
2025-01-01 |
Arcellx Inc |
Therapies with multifunctional immune system cells
|
|
CN111726985B
(zh)
*
|
2017-11-15 |
2022-06-10 |
弗里德里克·米谢尔生物医学研究所 |
灵长类动物视网膜色素上皮细胞特异性启动子
|
|
SG11202004527YA
(en)
*
|
2017-11-15 |
2020-06-29 |
Univ Michigan Regents |
Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
|
|
MA50877A
(fr)
|
2017-11-21 |
2020-09-30 |
Bayer Healthcare Llc |
Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
|
|
CN108085316B
(zh)
*
|
2017-12-25 |
2021-02-09 |
中国人民解放军第四军医大学 |
一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
|
|
WO2019183630A2
(en)
*
|
2018-03-23 |
2019-09-26 |
The Trustees Of Columbia University In The City Of New York |
Gene editing for autosomal dominant diseases
|
|
CN112543766A
(zh)
|
2018-04-03 |
2021-03-23 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
US20210363191A1
(en)
|
2018-04-03 |
2021-11-25 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
CA3094465A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
CA3096293A1
(en)
|
2018-04-27 |
2019-10-31 |
Rocket Pharmaceuticals, Ltd. |
Gene therapy for cns degeneration
|
|
SG11202011296VA
(en)
|
2018-05-15 |
2020-12-30 |
Voyager Therapeutics Inc |
Compositions and methods for the treatment of parkinson's disease
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
US12338267B2
(en)
|
2018-05-15 |
2025-06-24 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
EP3793615A2
(en)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Directed evolution of aav to improve tropism for cns
|
|
CA3102095A1
(en)
*
|
2018-06-01 |
2019-12-05 |
University Of Florida Research Foundation, Incorporated |
Compositions and methods for treatment of dominant retinitis pigmentosa
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
EP3830265A1
(en)
|
2018-08-03 |
2021-06-09 |
Genzyme Corporation |
Variant rnai against alpha-synuclein
|
|
CN109022487A
(zh)
*
|
2018-08-15 |
2018-12-18 |
上海市第人民医院 |
一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
|
|
WO2020068990A1
(en)
|
2018-09-26 |
2020-04-02 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
WO2020077091A1
(en)
*
|
2018-10-10 |
2020-04-16 |
Wisconsin Alumni Research Foundation |
Kir 7.1 gene therapy vectors and methods of using the same
|
|
EP4461814A3
(en)
*
|
2018-10-12 |
2025-02-26 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US20230061069A1
(en)
*
|
2018-11-13 |
2023-03-02 |
Jayandharan Giridhara Rao |
A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
|
|
CN113227126A
(zh)
*
|
2018-11-26 |
2021-08-06 |
巴塞罗那自治大学 |
成纤维细胞生长因子21(fgf21)基因治疗
|
|
WO2020117715A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
KR20210112339A
(ko)
*
|
2019-01-04 |
2021-09-14 |
울트라제닉스 파마수티컬 인코포레이티드 |
윌슨병을 치료하기 위한 유전자 요법 구축물
|
|
JP2022522995A
(ja)
|
2019-01-18 |
2022-04-21 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖ粒子を生成するための方法及びシステム
|
|
US20220133909A1
(en)
*
|
2019-01-23 |
2022-05-05 |
University Of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
|
|
EP3917944A1
(en)
|
2019-01-28 |
2021-12-08 |
Cohbar Inc. |
Therapeutic peptides
|
|
BR112021015312A2
(pt)
|
2019-02-04 |
2021-11-09 |
Freeline Therapeutics Ltd |
Polinucleotídeos, partícula viral e composição
|
|
US12491264B2
(en)
|
2019-03-04 |
2025-12-09 |
Duke University |
Compositions and methods for the diagnosis and treatment of retinopathies
|
|
WO2020180951A1
(en)
*
|
2019-03-04 |
2020-09-10 |
Adverum Biotechnologies, Inc. |
Sequential intravitreal administration of aav gene therapy to contralateral eyes
|
|
WO2020182722A1
(en)
*
|
2019-03-08 |
2020-09-17 |
Universite Paris-Saclay |
Improved therapeutic method for rare ocular diseases by gene replacement
|
|
BR112021018776A2
(pt)
|
2019-03-21 |
2021-11-30 |
Stridebio Inc |
Vetores de vírus adenoassociado recombinante
|
|
CA3136117A1
(en)
*
|
2019-04-10 |
2020-10-15 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
EP3969070B1
(en)
*
|
2019-05-13 |
2026-03-11 |
University of Pittsburgh - of the Commonwealth System of Higher Education |
Polymer-based implant for retinal therapy and methods of making and using the same
|
|
JP2022533645A
(ja)
*
|
2019-05-17 |
2022-07-25 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
グリコシドヒドロラーゼ酵素を使用する網膜細胞への遺伝子治療ベクターの送達の改善
|
|
EP3980447A4
(en)
*
|
2019-06-10 |
2023-07-26 |
Homology Medicines, Inc. |
ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR ARSA GENE TRANSFER AND METHODS OF USE THEREOF
|
|
AU2020308909A1
(en)
*
|
2019-06-27 |
2022-01-27 |
University Of Florida Research Foundation, Incorporated |
Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
PL3999119T3
(pl)
*
|
2019-07-15 |
2025-02-10 |
Meiragtx Uk Ii Limited |
Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów
|
|
CN110295151A
(zh)
*
|
2019-07-17 |
2019-10-01 |
博鑫仪器(天津)有限公司 |
一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
|
|
US20220281930A1
(en)
*
|
2019-08-23 |
2022-09-08 |
Duke University |
Compositions and methods for the treatment of pathological pain and itch
|
|
EP4025258A4
(en)
*
|
2019-09-03 |
2023-09-06 |
University of Cincinnati |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
CN114787179A
(zh)
*
|
2019-10-10 |
2022-07-22 |
坚固生物科技公司 |
经修饰的aav衣壳及其用途
|
|
KR20220083714A
(ko)
|
2019-10-17 |
2022-06-20 |
스트라이드바이오 인코포레이티드 |
니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
|
|
WO2021081217A1
(en)
*
|
2019-10-23 |
2021-04-29 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
EP4055030A4
(en)
*
|
2019-11-08 |
2024-05-22 |
President And Fellows Of Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
US20210261625A1
(en)
|
2020-01-29 |
2021-08-26 |
Genzyme Corporation |
Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
|
|
JP2023513208A
(ja)
*
|
2020-02-07 |
2023-03-30 |
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク |
神経変性の発症を遅延させるかまたは神経変性を処置するためのメタボロームのリプログラミング
|
|
US20230013145A1
(en)
*
|
2020-02-18 |
2023-01-19 |
The University Of North Carolina At Chapel Hill |
Aav capsid-promoter interactions and cell selective gene expression
|
|
WO2021173984A2
(en)
*
|
2020-02-28 |
2021-09-02 |
University Of Massachusetts |
Oligonucleotides for prnp modulation
|
|
US12257320B2
(en)
|
2020-03-11 |
2025-03-25 |
Massachusetts Eye And Ear Infirmary |
Gene therapy for NMNAT1-associated retinal degeneration
|
|
WO2021202494A1
(en)
*
|
2020-03-31 |
2021-10-07 |
University Of Massachusetts |
Aav capsids variants and uses thereof
|
|
EP4135776A1
(en)
*
|
2020-04-14 |
2023-02-22 |
Genethon |
Vectors for the treatment of acid ceramidase deficiency
|
|
MX2022012752A
(es)
|
2020-04-15 |
2023-01-16 |
Voyager Therapeutics Inc |
Compuestos de union a tau.
|
|
CN116096734A
(zh)
|
2020-05-13 |
2023-05-09 |
沃雅戈治疗公司 |
Aav衣壳的向性的重定向
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
EP4165193A4
(en)
*
|
2020-06-13 |
2024-07-24 |
Oculogenex Inc. |
AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY
|
|
CN113952472A
(zh)
*
|
2020-07-21 |
2022-01-21 |
英斯培瑞有限公司 |
用于治疗眼部疾病的组合物和方法
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
BR112023001336A2
(pt)
|
2020-08-05 |
2023-02-14 |
Spacecraft Seven Llc |
Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)
|
|
JP2023538519A
(ja)
|
2020-08-07 |
2023-09-08 |
スペースクラフト セブン リミテッド ライアビリティ カンパニー |
Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療
|
|
EP4200408A1
(en)
|
2020-08-19 |
2023-06-28 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus vectors for treatment of rett syndrome
|
|
AU2021335601A1
(en)
*
|
2020-09-04 |
2023-04-06 |
Ohio State Innovation Foundation |
Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain
|
|
US20230392166A1
(en)
*
|
2020-10-21 |
2023-12-07 |
Wisconsin Alumni Research Foundation |
Anti-apoptotic vector and method of using the same
|
|
US20220160825A1
(en)
*
|
2020-11-25 |
2022-05-26 |
The Penn State Research Foundation |
Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
|
|
KR20230148207A
(ko)
*
|
2021-02-22 |
2023-10-24 |
더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 |
안구 병태에 대한 바이러스 벡터-기반 유전자 요법
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
US20240218396A1
(en)
*
|
2021-04-26 |
2024-07-04 |
Grace Science, Llc |
Compositions and methods for treating ngyl1 deficiency
|
|
EP4333903A4
(en)
*
|
2021-05-03 |
2025-03-19 |
North Carolina State University |
COMPOSITIONS AND METHODS RELATED TO THE TREATMENT OF OPHTHALMIC DISEASES IN HORSES
|
|
AU2022340595A1
(en)
*
|
2021-09-06 |
2024-04-18 |
Huidagene Therapeutics (Singapore) Pte. Ltd. |
Treatment of rpe65-associated eye diseases and disorders
|
|
EP4433490A2
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CA3238867A1
(en)
|
2021-11-29 |
2023-06-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
CN118660913A
(zh)
|
2022-02-21 |
2024-09-17 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
WO2023183623A1
(en)
*
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
WO2023202637A1
(en)
*
|
2022-04-19 |
2023-10-26 |
Shanghai Vitalgen Biopharma Co., Ltd. |
Recombinant aav vectors for treating neurodegenerative disorders
|
|
CN119451703A
(zh)
*
|
2022-04-25 |
2025-02-14 |
迈特勒公司 |
髓鞘病症的治疗
|
|
AU2023260469A1
(en)
|
2022-04-25 |
2024-11-14 |
Cell Cure Neurosciences, Ltd. |
Methods and compositions for treating vision loss
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
WO2023240220A1
(en)
*
|
2022-06-09 |
2023-12-14 |
The University Of North Carolina At Chapel Hill |
Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
EP4551253A1
(en)
|
2022-07-08 |
2025-05-14 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes
|
|
WO2024015794A2
(en)
*
|
2022-07-12 |
2024-01-18 |
The Research Institute At Nationwide Children's Hospital |
Adeno-associated virus gene therapy products and methods
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024218311A1
(fr)
|
2023-04-21 |
2024-10-24 |
Pulsesight Therapeutics |
Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
|
|
GB202306952D0
(en)
*
|
2023-05-11 |
2023-06-28 |
Neurochase Innovations Ltd |
Method
|
|
WO2025040166A1
(zh)
|
2023-08-23 |
2025-02-27 |
上海瑞宏迪医药有限公司 |
药物组合物及其用途
|
|
WO2025128817A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
Artificial micrornas targeting tau
|
|
WO2025160452A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Methods for fus-based delivery of viral particles to the brain
|
|
TW202548014A
(zh)
|
2024-01-26 |
2025-12-16 |
美商健臻公司 |
靶向亨丁頓舞蹈症之人工ｍｉｃｒｏｒｎａ
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
CN120829932A
(zh)
*
|
2024-04-18 |
2025-10-24 |
临港国家实验室 |
治疗眼部疾病的药物组合物及方法
|